Anti-IL-5 and anti-IL-5 receptor antibody treatment significantly decrease the frequency of asthma exacerbations and the use of systemic glucocorticoids, improving lung function and quality of life [31,32,33,34,35]. The gene discussed is IL5; the disease is asthma.